Bicara Therapeutics Inc. - Common Stock (Nasdaq:BCAX) Detailed Stock Data
This article provides detailed stock data for Bicara Therapeutics Inc. (Nasdaq: BCAX), including its current price, daily change, volume, and key financial metrics like EPS and price/earnings. It also presents price performance over various periods, such as year-to-date and 1-year changes, reflecting a significant increase in value.
Bicara Therapeutics' President Ryan Cohlhepp Reports Stock Option Exercise and Share Sales in Form 4 Filing
Ryan Cohlhepp, President, COO, and Interim CEO of Bicara Therapeutics Inc., exercised stock options for 17,500 common shares and subsequently sold all of them in two tranches on September 8, 2026. These transactions were executed under a Rule 10b5-1 trading plan. Following the sales, Cohlhepp directly holds 181,641 shares and retains 34,252 stock options.
Cantor Fitzgerald reiterates Overweight on Bicara stock
Cantor Fitzgerald reiterated an Overweight rating on Bicara Therapeutics (NASDAQ: BCAX) stock, citing the undervaluation of the company given the potential of its drug ficerafusp in the HPV-negative head and neck squamous cell carcinoma market. The firm projects $1.5 billion in peak sales for ficerafusp and noted that growing anticipation of mid-2027 Phase 3 interim results could further boost share appreciation. Several other analyst firms, including Citizens, BMO Capital, Mizuho, BTIG, and Morgan Stanley, have also shown confidence in Bicara with positive ratings and increased price targets.
BCAX 8-K Filings - Bicara Therapeutics Inc. SEC 8-K
This article provides a compilation of Bicara Therapeutics Inc.'s (BCAX) 8-K filings with the SEC over the last 24 months, detailing material events such as corporate headquarters sublease agreements, financial results, leadership changes, clinical trial advancements, and equity offerings. Each entry includes a summary generated by Rhea-AI, offering insights into significant company developments. The filings cover a range of strategic and operational updates relevant to investors and stakeholders.
Bicara interim CEO sells 17,500 shares after option exercise | BCAX Insider Trading
Bicara Therapeutics Inc. (BCAX) interim CEO, Ryan Cohlhepp, exercised options to acquire 17,500 shares at $3.7898 per share and subsequently sold all these shares in multiple transactions on September 8, 2026. The sales were executed under a Rule 10b5-1 trading plan adopted on March 31, 2026, with shares selling at weighted average prices of $22.7666 and $23.4349. Following these transactions, Cohlhepp retains 34,252 options and 181,641 common shares.
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics announced inducement grants under Nasdaq Listing Rule 5635(c)(4), awarding non-qualified stock options to two new employees on September 1, 2026. This includes a grant of 275,000 shares to their new Chief Legal Officer, Gregory Shiferman. These awards were made as a material inducement to employment and vest over several years, subject to continued service.
Boston biotech Bicara signs sublease for Wayfair space
Bicara Therapeutics, a Boston-based biotech company, is relocating its headquarters to a subleased space previously occupied by Wayfair in Back Bay. The company, which reported 103 employees in March, is transitioning from a clinical-stage organization to a commercial-stage one and will occupy the entire fourth floor of 10 St. James Ave.
Citizens reiterates Bicara Therapeutics stock rating on trial progress
Citizens has reiterated a Market Outperform rating and a $31.00 price target for Bicara Therapeutics (NASDAQ:BCAX), citing the company's strong cash position, advancing pivotal trial, and potential for significant upside. Despite a 110% return over the past year, InvestingPro analysis suggests the stock may be overvalued relative to its Fair Value. Other analysts like Morgan Stanley, BTIG, Mizuho, and BMO Capital have also adjusted their targets and ratings positively, reflecting optimism about the company's drug candidates and financial runway into 2029.
Citizens reiterates Bicara Therapeutics stock rating on trial progress
Citizens reiterated a Market Outperform rating and $31.00 price target on Bicara Therapeutics Inc (NASDAQ:BCAX), based on discounted EPS and revenue multiple analysis. The company reported strong financial results for Q2 2026, including a cash position of $497.3 million, and its pivotal trial is progressing rapidly with data expected in the second half of 2026. Despite a 110% return over the past year, InvestingPro analysis suggests BCAX may be overvalued relative to its Fair Value estimate.
Bicara Therapeutics (NASDAQ:BCAX) Raised to "Strong-Buy" at BMO Capital Markets
BMO Capital Markets upgraded Bicara Therapeutics (NASDAQ:BCAX) to a "strong-buy" rating, with other analysts maintaining a "Moderate Buy" consensus and an average target price of $32.64. The company's shares rose by 3.8% to $25.86, following a quarterly EPS report of negative $0.82, which met consensus estimates. Insider selling occurred last quarter, but major institutional investors like BlackRock and Janus Henderson increased their holdings.
Bicara Therapeutics Initiated at Outperform by BMO Capital
BMO Capital has initiated coverage on Bicara Therapeutics with an Outperform rating. This indicates a positive outlook from the firm regarding the company's future performance. The specific reasons for this rating are not detailed in this short blurb.
BMO Capital Initiates Bicara Therapeutics at Outperform
BMO Capital has initiated coverage on Bicara Therapeutics with an Outperform rating. This rating suggests that BMO Capital expects Bicara Therapeutics' stock to perform better than the broader market or its sector peers. The initiation of coverage by a major financial institution like BMO Capital often brings increased attention and potential investor interest to the company.
BICARA THERAPEUTICS INC : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $35
BMO has initiated coverage on Bicara Therapeutics Inc. (BCAX.O) with an Outperform rating. The financial institution has set a price target of $35 for the company's stock. This news indicates a positive outlook from BMO regarding Bicara Therapeutics' future performance.
BMO starts Bicara Therapeutics stock at Outperform on cancer drug potential
BMO Capital initiated coverage on Bicara Therapeutics (NASDAQ:BCAX) with an Outperform rating and a $35 price target, citing the potential of its bispecific drug candidate, ficerafusp alfa, for head and neck squamous cell carcinoma. The firm anticipates a key value inflection point in mid-2027 and potential accelerated approval by 2028, projecting peak sales of $2 billion. Other analysts also maintain positive outlooks, with price targets ranging up to $39, despite the stock's significant surge over the past year.
Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Rating of "Moderate Buy" by Brokerages
Bicara Therapeutics Inc. (NASDAQ:BCAX) has received an average "Moderate Buy" rating from fourteen analysts, with an average 12-month price target of $32.40. Despite insider share sales by the CEO and CFO totaling approximately $3.27 million over the past quarter, the company reported a quarterly loss of $0.82 per share, matching analyst expectations. Bicara Therapeutics is a clinical-stage biopharmaceutical company focusing on neurohormone-based therapies for psychiatric and neurological disorders.
Bicara Therapeutics (BCAX) Is Down 13.5% After Leadership Overhaul And ESOP Shelf Filing - Has The Bull Case Changed?
Bicara Therapeutics (BCAX) has seen a 13.5% drop following a significant leadership reshuffle, including new executives for CEO, CFO, COO, Chief Business Officer, and Chief Legal Officer roles. This overhaul, coupled with a wider net loss of US$55.44 million and an ESOP shelf filing for up to 700,000 shares, signals a shift towards commercialization, particularly for ficerafusp alfa. Investors are now evaluating whether these changes and the associated dilution risk will impact the company's investment narrative ahead of the mid-2027 interim trial readout.
BCAX Stock Price and Chart — NASDAQ:BCAX
This article provides a comprehensive overview of Bicara Therapeutics Inc. (BCAX) stock, including its current price, historical performance, key financial statistics, and analyst ratings. It details company information such as its sector, industry, CEO, and product pipeline, BCA101. The report also includes recent earnings summaries, employee data, and a list of ETFs holding BCAX stock.
SCS Capital Management LLC Purchases New Shares in Bicara Therapeutics Inc. $BCAX
SCS Capital Management LLC has acquired 53,430 shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) worth approximately $1.586 million, establishing a new position in the company. Despite insider selling activity totaling $3.27 million, other institutional investors have also adjusted their holdings. Analysts maintain a "Moderate Buy" rating for Bicara Therapeutics with an average price target of $32.73, while the company reported a quarterly loss in line with expectations.
Walleye Capital LLC Makes New $10.49 Million Investment in Bicara Therapeutics Inc. $BCAX
Walleye Capital LLC has made a new $10.49 million investment in Bicara Therapeutics Inc. (NASDAQ:BCAX), acquiring 353,226 shares, representing approximately 0.54% of the company. Other institutional investors also increased their stakes, while company insiders sold shares worth $3.27 million over the past three months. Analysts maintain a "Moderate Buy" consensus rating with an average target price of $32.73 for BCAX.
Bicara Therapeutics (BCAX) awards 285,000 stock options to CFO Jennifer Larson
Bicara Therapeutics Inc. has granted 285,000 stock options to its CFO, Jennifer Larson, on August 12, 2026, with an exercise price of $24.63 per share. These options will vest over time, with 25% vesting on August 12, 2027, and the remainder in equal quarterly installments, contingent on her continued service. Following this grant, Ms. Larson directly holds 285,000 derivative securities of this type, which expire on August 12, 2036.
Bicara Therapeutics (BCAX) CFO Jennifer Larson submits initial Form 3
Bicara Therapeutics Inc.'s Chief Financial Officer, Jennifer Larson, has submitted an initial Form 3, indicating her status as an officer but showing no reportable equity holdings or transactions at this time. The filing includes a reference to an attached Exhibit 24, which grants a Power of Attorney. This Form 3 serves as the initial statement of beneficial ownership for the CFO of BCAX.
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics Inc. announced an inducement grant to Jennifer Larson, its new Chief Financial Officer, effective August 12, 2026. Ms. Larson received a non-qualified stock option to purchase 285,000 shares of common stock at an exercise price of $24.63 per share, vesting over approximately four years. This grant was made under Bicara's 2026 Inducement Plan and was approved by independent directors as a material inducement for her employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics announced an inducement grant to Jennifer Larson, the new Chief Financial Officer, under Nasdaq Listing Rule 5635(c)(4). Ms. Larson received a non-qualified stock option to purchase 285,000 shares of Bicara's common stock at an exercise price of $24.63 per share. This grant vests over time, with a quarter vesting on her first anniversary and the remainder in quarterly installments, contingent on her continued employment.
Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAX
Dimensional Fund Advisors LP significantly increased its stake in Bicara Therapeutics Inc. by 166.9% in the first quarter, now holding 109,261 shares valued at $2.17 million. Several other institutional investors also raised their positions, while insider sales have occurred. Bicara Therapeutics maintains a "Moderate Buy" consensus rating with an average price target of $32.73, and investors are looking forward to clinical progress, particularly the planned 2026 enrollment for the ficerafusp alfa study.
Bicara Therapeutics (NASDAQ:BCAX) COO Sells $524,625.00 in Stock
Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp sold 18,750 shares of the company's stock for $524,625 under a pre-arranged Rule 10b5-1 plan, reducing his position by 9.36%. The company's stock rose 3.7% to $24.63, and it reported a quarterly loss of $0.82 per share, matching analyst expectations. Analyst sentiment for BCAX is mixed but generally positive, with a consensus "Moderate Buy" rating and an average price target of $32.73.
Bicara Therapeutics (BCAX) CFO exercises options, sells 12,500 shares under 10b5-1 plan
Bicara Therapeutics Inc.'s Chief Financial Officer, Hyep Ivan, exercised stock options for 12,500 shares at $3.7898 per share and simultaneously sold these shares at a weighted average price of $27.9673 per share. These transactions, executed on August 10, 2026, were conducted under a Rule 10b5-1 trading plan adopted on March 31, 2026. Following these trades, Ivan's reported option position decreased to 26,336 stock options, which vest in quarterly installments and expire in 2033.
Bicara Therapeutics (BCAX) President & COO exercises 18,750 options and sells 18,750 shares
Bicara Therapeutics Inc. President and COO Ryan Cohlhepp exercised 18,750 stock options at $3.7898 per share and simultaneously sold 18,750 common shares at a weighted average price of $27.9751. This transaction was conducted under a Rule 10b5-1 trading plan adopted on March 31, 2026. Following these transactions, Cohlhepp retains 51,752 stock options expiring in 2033 and 181,641 common shares.
Bicara Therapeutics Insider Sold Shares Worth $524,533, According to a Recent SEC Filing
An insider at Bicara Therapeutics sold shares valued at $524,533, as per a recent SEC filing. This transaction is one of several insider sales reported for the company around the same date, alongside other corporate news including earnings reports and analyst rating adjustments.
Mizuho raises Bicara Therapeutics stock price target on HNSCC positioning
Mizuho has increased its price target for Bicara Therapeutics (NASDAQ: BCAX) to $20 from $18, citing improved positioning for its ficera drug in head and neck squamous cell carcinoma. The company recently reported Q2 2026 earnings, provided pipeline updates, and announced executive leadership changes. Despite competitive risks, Bicara expects substantial enrollment in its FORTIFI-HN01 trial by end-2026 and interim data by mid-2027.
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
Bicara Therapeutics Inc. reported better-than-expected Q2 losses of 82 cents per share, surpassing analyst estimates. Following the earnings, BTIG and Wells Fargo analysts adjusted their price targets for BCAX, with BTIG maintaining a "Buy" rating and raising its price target from $28 to $39, and Wells Fargo maintaining an "Equal-Weight" rating and raising its target from $16 to $23. Despite beating estimates, the company's shares dipped 14.3% to $23.76.
Bicara Therapeutics Inc. 2026: Revenue ($55.76M), Net income ($55.44M), EPS ($0.82) — 10-Q Summary
Bicara Therapeutics Inc. reported a wider loss in 2026 compared to the previous year, with a total comprehensive loss of ($55.76M) and a net loss of ($55.44M). This was attributed to increased clinical and development activity as the company prepares for a planned Phase 3 program for its FORTIFI-HN01 program. The company also highlighted positive trial signals from Phase 1b, dose flexibility initiatives, and operational scale-up, including increased staffing and spending.
Mizuho raises Bicara Therapeutics stock price target on HNSCC positioning
Mizuho increased its price target for Bicara Therapeutics (NASDAQ:BCAX) to $20 from $18, citing improved positioning of its ficera drug candidate for head and neck squamous cell carcinoma. The company reported Q2 2026 earnings, updated its pipeline, and announced executive leadership changes. Bicara anticipates completing enrollment for the FORTIFI-HN01 trial by year-end 2026 and releasing interim topline data in mid-2027, with initial data for ficera in colorectal cancer expected by the end of 2026.
Bicara Therapeutics Reports Second Quarter 2026 Progress
Bicara Therapeutics announced its second-quarter 2026 financial results and significant leadership transitions, including Ryan Cohlhepp becoming President & CEO in January 2027. The company is on track for substantial enrollment in its pivotal FORTIFI-HN01 study by year-end, with topline results expected mid-2027, and reported $497.3 million in cash, cash equivalents, and marketable securities, projected to fund operations into the first half of 2029. They also initiated the FORTIFI-FLEX alternate dosing study and presented positive extended follow-up data for ficerafusp alfa in HPV-negative HNSCC.
Bicara Therapeutics (BCAX) deepens R&D investment while holding $497M in cash
Bicara Therapeutics (BCAX) reported a net loss of $55.4 million for Q2 2026 and $111.6 million for the first half of 2026, primarily due to increased R&D and administrative expenses. Despite the larger loss, the clinical-stage oncology company holds a strong cash position of $497.3 million, expected to fund operations into the first half of 2029. The company is advancing its lead asset, ficerafusp alfa, through a pivotal Phase 2/3 trial and other studies for solid tumors.
Morgan Stanley raises Bicara Therapeutics stock price target on cash runway
Morgan Stanley has increased its price target for Bicara Therapeutics (NASDAQ:BCAX) from $37 to $39, maintaining an Overweight rating due to the company's strong cash position. Bicara reported $497.3 million in cash and equivalents, projected to fund operations into the first half of 2029, a factor influencing the updated discounted cash flow analysis. Despite a significant 177% return over the past year, the stock is currently considered overvalued relative to its fair value.
Bicara Therapeutics Releases Q2 2026 Financial Results
Bicara Therapeutics Inc. (BCAX) reported a narrower-than-expected loss of $0.82 per share for Q2 2026, surpassing Wall Street's estimate of a $0.85 loss. Despite this, the company's net loss widened to $55.4M as it continues significant investments in its clinical development programs for bifunctional therapies targeting solid tumors. Analyst sentiment remains positive with 10 buy ratings and 4 hold ratings, reflecting confidence in its therapeutic approach despite ongoing operating losses.
Bicara Therapeutics Inc. (BCAX) Investor Outlook: Tapping into a 14% Upside with Innovative Biotech Solutions
Bicara Therapeutics Inc. (BCAX) is a clinical-stage biopharmaceutical company focused on innovative cancer treatments, particularly bifunctional therapies for solid tumors. Despite operating at a loss, which is common for early-stage biotech firms, analysts project a 14.36% upside for the stock, driven by its promising pipeline and investor confidence. The company's lead program, ficerafusp alfa, is a cutting-edge bifunctional antibody that highlights its commitment to redefining cancer treatment.
Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
Bicara Therapeutics Inc. announced it will report its second-quarter 2026 financial results and provide business updates on August 11, 2026, before market open. The company will host a conference call and webcast at 8:30 AM ET on the same day to discuss these results. Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, with its lead program ficerafusp alfa targeting EGFR and TGF-β.
Bicara Therapeutics (BCAX.US) will release its earnings report before market open on August 11.
Bicara Therapeutics (BCAX.US) is scheduled to release its earnings report on August 11, before the market opens. This announcement informs investors and the public about the upcoming financial disclosure.
Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET
Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company, announced it will report its second-quarter 2026 financial results and provide business updates on Tuesday, August 11, 2026, before market open. The company will host a conference call at 8:30 a.m. ET on the same day to discuss these results. Bicara focuses on developing transformative bifunctional therapies for solid tumors, with its lead program ficerafusp alfa currently in development.
Bicara Therapeutics Q2 Results: Financial update scheduled for August 11, 2026
Bicara Therapeutics Inc. will release its Q2 2026 financial results on August 11, 2026, before market open, followed by a conference call at 8:30 a.m. ET. The company, a clinical-stage biopharmaceutical firm, is focused on developing bifunctional therapies for solid tumors, with its lead program ficerafusp alfa targeting head and neck squamous cell carcinoma and other solid tumor types. A webcast of the call will be available on the company's investor relations page, with a replay accessible for 30 days.
Bicara Therapeutics will detail second-quarter results Aug. 11
Bicara Therapeutics (NASDAQ: BCAX) announced it will report its second quarter 2026 financial results and provide business updates before the market opens on Tuesday, August 11, 2026. The company will host a conference call at 8:30 a.m. ET the same day to discuss these updates. Investors can register online to receive dial-in details and a unique PIN for the call, and a live webcast will be available via the company's website.
Bicara Therapeutics to Report Second Quarter 2026 Financial
Bicara Therapeutics Inc. announced it will report its second quarter 2026 financial results and business updates on Tuesday, August 11, 2026, before the market opens. The company will host a conference call at 8:30 a.m. ET on the same day to discuss these updates. Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, with its lead program ficerafusp alfa targeting EGFR and TGF-β.
Rock Springs Capital Management LP Raises Stock Holdings in Bicara Therapeutics Inc. $BCAX
Rock Springs Capital Management LP increased its stake in Bicara Therapeutics Inc. by 14% in the first quarter, now holding 489,095 shares valued at $9.7 million. Despite the company missing its Q1 earnings estimates with a loss of $0.93 per share, Bicara's stock opened 2.9% higher at $27.81. Analysts maintain a "Moderate Buy" rating for BCAX with an average price target of $30.27, although insiders have recently sold shares worth approximately $2.37 million.
Will New Oncology Veterans on Bicara Therapeutics' (BCAX) Board Reshape Its Late-Stage Strategy?
Bicara Therapeutics (BCAX) has appointed Jeremy Bender and Christy Oliger to its Board of Directors, bringing extensive oncology drug development and commercialization experience. These appointments could significantly influence the company's late-stage strategy for its lead asset, FICERA, particularly concerning its FORTIFI HN01 trial and future commercialization. The article discusses how these new board members might reshape the company's investment narrative and risk profile, especially as Bicara aims for substantial revenue growth by 2029.
Bicara Therapeutics (BCAX) director reports initial Form 3 filing
Bicara Therapeutics Inc. director Christy J. Oliger has filed an initial Form 3, an Initial Statement of Beneficial Ownership. The filing indicates no current equity or derivative security holdings and no reported transactions, with a reference to a Power of Attorney document. This report signifies the initial disclosure of ownership for a newly appointed director.
Will New Oncology Veterans on Bicara Therapeutics' (BCAX) Board Reshape Its Late-Stage Strategy?
Bicara Therapeutics recently appointed Jeremy Bender and Christy Oliger, experienced oncology executives, to its Board of Directors, while Kiran Mazumdar-Shaw retired. These appointments are expected to influence Bicara's late-stage development and commercialization decisions, particularly regarding its FICERA program for head and neck cancer. Investors will be watching how this expertise shapes trial execution and launch planning, though the core risk/reward of the single-asset focus remains.
Bicara Therapeutics (BCAX) awards 38,950 stock options to board director
Bicara Therapeutics (BCAX) director Christy J. Oliger was granted 38,950 stock options with an exercise price of $26.88 per share, expiring on July 28, 2036. The options will vest one-third on July 28, 2027, with the remainder vesting in 24 equal monthly installments, contingent on her continued service. This transaction is an equity-based compensation and not an open-market purchase or sale.
Bicara Therapeutics grants options to director | BCAX Insider Trading
Bicara Therapeutics (BCAX) has granted its director, Jeremy Bender, 38,950 stock options. These options have an exercise price of $26.88 per share and expire on July 28, 2036. The shares will vest in stages, with one-third vesting on July 28, 2027, and the remainder vesting in 24 equal monthly installments, contingent on Bender's continued service.
Bicara Therapeutics Inc. (BCAX) director Jeremy Bender files ownership report
Bicara Therapeutics Inc. director Jeremy Bender has filed an initial statement of beneficial ownership (Form 3), indicating his role as a director. The filing reports no transactions or specific equity holdings for Bender and refers to an accompanying Exhibit 24 - Power of Attorney. This filing clarifies that Bender does not currently hold any direct equity or derivative securities in BCAX, as of the reporting date.
